EU GMP Annex 21 (Importation of Medicinal Products)
A practical guide to EU/EEA medicinal-product importation, from authorised site responsibilities and physical receipt to testing, QP certification and controlled stock transfer.

On this page · 11 sections
- 1What Annex 21 means for medicinal-product importers
- 2Legal basis: legislation, MIA conditions and GMP guidance
- 3Scope boundaries: products, territories and export-only movements
- 4From physical importation to controlled stock transfer
- 5Allocate MIA-holder, MAH and Qualified Person responsibilities
- 6Importation testing and the limits of MRA reliance
- 7Batch documentation, technical agreements and review depth
- 8Connect batch identity, import events and decision evidence
- 9Importation failure modes and controlled exception recovery
- 10Annex 21 versus Annex 16 and neighbouring GMP guidance
- 11Implementation and review checklist for an importation route
How does EU GMP Annex 21 (Importation) apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01What Annex 21 means for medicinal-product importers
Annex 21 (Importation of Medicinal Products) is EU GMP guidance summarising the GMP requirements applicable to Manufacturing Import Authorisation (MIA) holders importing human, investigational and veterinary medicinal products from outside the EU/EEA. Annex 21, section 1 sets out that scope.
Its introductory legal-basis statement identifies it as guidance interpreting GMP principles and guidelines—not a standalone legislative instrument. The relationship between legislation, authorisation conditions and this guidance is addressed in the following section. For broader terminology, see current good manufacturing practice.
Before applying individual provisions, organise the import route around three practical questions. These are an operational navigation aid, not a statutory three-part test:
- Does the shipment fall within scope? Identify the product category, origin, destination and intended use before selecting the relevant controls.
- Which authorised site owns each importation activity? Map the organisations and sites involved, with named responsibility for each handover rather than treating “the importer” as one undifferentiated role.
- Which evidence supports the eventual batch decision? Identify the batch records, testing information and movement records needed to explain the decision and connect it to the correct product and batch.
A useful starting document is a route summary linking those three answers. Use it to navigate the detailed scope, workflow and responsibility checks that follow.
02Legal basis: legislation, MIA conditions and GMP guidance
Separate three layers: applicable medicines legislation, the holder’s Manufacturing Import Authorisation (MIA), and GMP guidance. Check binding obligations against the current legislation and the MIA’s scope and conditions; use Annex 21 to interpret GMP for importation, not as a standalone statute or authorisation.
Annex 21’s legal-basis statement cites Article 47 of Directive 2001/83/EC for human medicines and Regulation 2019/6 for veterinary medicines. It also names Clinical Trials Regulation 536/2014 and Commission Delegated Regulation 2017/1569. These references explain the guidance’s legislative setting; they are not a complete statement of current operative law.
| Product and territory | Legislative framework to check | GMP guidance | Authorisation context |
|---|---|---|---|
| Marketed human medicines imported into the EU/EEA | Directive 2001/83/EC, cited by Annex 21; check current applicable provisions. | Annex 21 for importation; Annex 16 for QP certification and batch release. | Check MIA scope and conditions alongside the relevant marketing authorisation (MA). |
| Human investigational medicinal products imported into the EU/EEA | Clinical Trials Regulation 536/2014 and Commission Delegated Regulation 2017/1569, named by Annex 21. | Annex 21; consult the related Annex 13 guidance. | Check MIA scope and conditions alongside the clinical trial authorisation (CTA), not a marketed-product authorisation route. |
| Veterinary medicinal products imported into the EU/EEA | Regulation 2019/6, cited by Annex 21; check current applicable veterinary legislation. | Annex 21, read against the current veterinary framework. | Check MIA scope and conditions alongside the relevant product authorisation. |
Annex 21 also references Directives 2003/94/EC and 91/412/EEC. Do not use older references as a complete current veterinary-law map. Its section 2.2 distinguishes the MA, CTA and relevant quality agreement “as applicable”: keep those route-specific documents separate in the regulatory assessment.
Annex 16’s scope statement identifies Article 51 of Directive 2001/83/EC as relevant legislation for human medicines. That legislative reference is distinct from Annex 16’s operational guidance on QP certification and batch release: use the legislation to establish the obligation and the guidance to interpret its GMP implementation.
03Scope boundaries: products, territories and export-only movements
Under Annex 21, section 2.1, importation means physically bringing a medicinal product into the EU/EEA from outside that territory; fiscal transactions are outside the annex. A commercial invoice or transfer of ownership is therefore not, by itself, the physical importation activity addressed by this guidance. Classify the movement of the goods, not simply the location of the buyer or the date of payment.
Annex 21, section 1 frames its scope around human, investigational and veterinary medicinal products imported from outside the EU/EEA. Its export-only exclusion combines three conditions: intended export only, no processing in any form, and no release for placing on the EU/EEA market. An eventual export destination alone does not establish the exclusion.
Worked case: two consignments intended for export
Assume two medicinal-product consignments enter the EU/EEA solely for eventual export. No quantities or measurement units affect this classification.
- Consignment A remains unprocessed and is not released for the EU/EEA market. On these assumptions, it meets the stated export-only exclusion.
- Consignment B undergoes further processing before export. It fails the no-processing condition, so the same exclusion cannot simply be assumed.
These are hypothetical route classifications, not country-specific customs advice. For a route involving a bonded warehouse, assess the planned activities against these conditions rather than relying on the warehouse label. Keep this scope assessment specific to medicinal products entering the EU/EEA; use separate regulatory assessments for food, supplements, devices, general chemicals and other destination jurisdictions.
04From physical importation to controlled stock transfer
For medicinal products imported into the EU/EEA, distinguish the GMP guidance sequence from the warehouse transactions used to implement it. Receipt, customs clearance, quarantine, QP certification or confirmation, and transfer to saleable stock describe different events—not interchangeable release statuses.
Under Annex 21, section 2.1, QP certification or confirmation takes place only after physical importation and customs clearance into an EU/EEA state's customs territory. Arrival and clearance are not substitutes for the QP decision.
Annex 21, section 4.2 says imported medicinal products should remain under quarantine after receipt until release for further processing or following QP certification or confirmation, as appropriate. It calls for segregated quarantine areas; a system replacing physical quarantine should provide equivalent security. A quarantine status therefore needs effective controls, not merely a label.
For medicinal products manufactured outside the EU, Annex 16, section 1.5 places physical importation and certification at the final manufacturing stages preceding transfer to saleable stock. Treat that stock transfer as a separate controlled event, not another name for certification.
As an operational practice, record receipt quantity and location, clearance evidence, quarantine status, the applicable QP decision, and the authorised inventory transition separately. This preserves the difference between where stock is located and what may be done with it.
Worked case 2: damage within quarantined stock
Assume one shipment contains 120 cartons, each holding 100 packs: 120 × 100 = 12,000 packs. Two cartons containing 200 packs have visible damage; the remaining 118 cartons contain 11,800 packs. Reconciliation is 11,800 + 200 = 12,000 packs.
Keep all 12,000 packs within quarantined inventory and identify the damaged 200 packs with an additional damage-related hold. Use bin-level lot genealogy to retain their location and batch association. Record the observation and route it for authorised assessment. The 11,800 apparently undamaged packs cannot be released on that basis alone, and this quantity breakdown does not authorise a batch split. Any later disposition and stock movement should follow the authorised decision, with quantities reconciled.
- Define routeIdentify product, authorisation and responsible MIA sites.
- Receive and clearLink physical importation and customs clearance to batch identity.
- Control quarantineMaintain restricted stock status during assessment.
- Assess testingEstablish complete results or applicable reliance.
- Review evidenceReconcile documentation, confirmations and quality exceptions.
- Record QP decisionPreserve certification or confirmation evidence, as appropriate.
- Control stock transferRecord the separately authorised inventory-status change.
05Allocate MIA-holder, MAH and Qualified Person responsibilities
Annex 21’s EU GMP guidance identifies two importation responsibility points: the site of physical importation and the site of QP certification, or QP confirmation for bulk or intermediate products undergoing further processing. Under Annex 21, section 2.1, these responsibilities must be carried out by entities appropriately authorised under a Manufacturing Import Authorisation (MIA). Allocate each activity to the relevant authorised entity, rather than treating “the importer” as an undifferentiated role.
For products authorised in the EU/EEA, Annex 21, section 2.3 places overall responsibility for putting the medicinal product on the market with the marketing authorisation holder (MAH). This is distinct from individual batch certification. Annex 16’s General principles make the certifying QP responsible for ensuring that each batch has been manufactured and checked against three distinct references: the laws of the Member State where certification occurs, the marketing authorisation (MA), and GMP.
Responsibility need not mean personally performing every operation. Annex 16, section 1.5.2 allows the finished-product certifying QP to take account of other QPs’ confirmations and share defined responsibilities for manufacturing or importation operations at other EU sites and other manufacturing authorisation holders defined in the relevant MA. The distinction between confirmation and certification is central to Annex 16’s batch-release framework.
As an industry-practice coordination aid—not a prescribed Annex 21 form—a responsibility matrix should identify:
- Activity: the operation and its boundaries.
- Authorised site: the entity and relevant MIA scope.
- Responsible person: who performs or approves the assigned work.
- Supporting confirmation: which QP confirmation supports the downstream decision.
- Escalation owner: who resolves missing information or disputed responsibility.
For bulk and intermediate products, section 2.1 also allows further manufacturing in accordance with the relevant marketing or clinical trial authorisation before QP certification or confirmation, as appropriate. Do not label an intermediate-stage confirmation as finished-product certification. In the matrix, describe the operations that confirmation covers and the subsequent decision it supports; this makes the handover explicit without merging the two roles.
06Importation testing and the limits of MRA reliance
For products with a marketing authorisation (MA), Annex 21, section 2.4 states that the certifying QP must ensure testing upon importation into the Union, unless appropriate arrangements apply between the Union and the third country. This is the Annex’s GMP guidance statement; its MA-specific testing wording should not be converted into an identical testing rule for every investigational medicinal product.
Assess the arrangement, not just the shipment origin
Section 2.4 names a Mutual Recognition Agreement (MRA) and an Agreement on conformity assessment and acceptance of industrial products (ACAA) as examples of appropriate arrangements. Their mention is not a blanket testing exemption for shipments from a particular country.
As a practical decision record, identify the arrangement relied upon, the product and activity scope considered, and the authorised assessment of its applicability. Record the basis for any testing relief rather than inferring it from the dispatch address. These are suggested decision-record fields, not a prescribed statutory template.
Worked case 3: eight specified tests, seven reported
Annex 21, section 2.5 says EU/EEA testing should cover all tests needed to demonstrate conformity with the specifications in the MA.
Assume an MA specifies eight tests, each requiring one reported result, and no applicable arrangement provides testing relief. The third-country Certificate of Analysis (CoA) contains eight results; the EU/EEA importation-testing report contains seven corresponding results. Eight required results minus seven reported results leaves one required result outstanding. Under these assumptions, the overseas CoA does not complete the local panel.
A useful reconciliation links each specified test to its result and report reference within the batch execution history. The gap is an unaccounted-for required result: the count alone does not establish whether testing was omitted or its documentation is missing. It establishes neither a retest deadline nor a batch-disposition outcome.
Separately, in the Product Quality Review (PQR) context, Annex 21, section 3.2 describes comparing importation-testing results with the third-country manufacturer’s CoA. Any discrepancies or out-of-trend (OOT) results should be documented and investigated. This comparison addresses analytical agreement, rather than merely counting completed tests.
07Batch documentation, technical agreements and review depth
For medicinal-product importation into the EU/EEA, Annex 21 provides GMP guidance on documentation responsibilities. Annex 21, section 2.6 calls for written agreements between sites performing manufacturing and importation activities and the marketing authorisation holder (MAH) or sponsor, as appropriate, in accordance with Chapter 7 of the EU GMP Guide.
Make document handoffs explicit
As practical agreement topics—not a prescribed template—define:
- Record handover: who provides the batch record, supporting results and subsequent corrections, and who receives them.
- Testing responsibility: who commissions testing, supplies results and resolves missing information.
- Deviation escalation: who communicates unresolved issues and routes them to the responsible reviewers.
- Decision communication: how certification or confirmation is communicated, with an identifiable batch and decision record.
Separate availability from review frequency
Annex 21, section 5.1 states that full batch documentation must be available to the manufacturing/importation authorisation (MIA) holder responsible for QP certification or confirmation at the time of that decision. Other MIA holders involved in importation should have access according to their site's activities, as reflected in the written agreements.
Availability of full documentation is distinct from how frequently the certification or confirmation site reviews it in full. Under Annex 21, section 5.1.1, that frequency should be justified by risk assessment and defined in the Pharmaceutical Quality System (PQS); it is not a universal calendar interval. The same section calls for documentary evidence demonstrating QP certification or confirmation against the marketing authorisation (MA) or clinical trial authorisation (CTA), including other applicable regulatory restrictions.
Annex 21, section 5.4 adds a supplier-oversight expectation: "There should be documentary evidence that the site performing QP certification has qualified the third country manufacturer and regularly monitors its performance by periodic on-site audits, either by the site performing QP certification or by a third party on its behalf in accordance with Annex 16 of the EU GMP Guide". As a practical control, distinguish source documents, review records and decision evidence in the document index, and keep the qualification and audit history for each third-country manufacturer retrievable from the batch it supports.
The two sites hold different documents. Under Annex 21, section 5.1.2, "The documentation on the site of physical importation should include, at a minimum, the details of transportation and receipt of the product". Section 5.1.3 then expects relevant ordering and delivery documentation to be available for inspection at the site responsible for QP certification or confirmation, clearly indicating the dispatch site (the origin of the product), the site of physical importation, and shipping details including transportation route and temperature monitoring records, together with customs documentation such as the packing list, freight documentation or customs import declaration, as applicable.
Two further documentation points are easy to overlook. Annex 21, section 5.2 states that documentation must be retained in accordance with Chapter 4 of the EU GMP Guide, and that the site responsible for QP certification should ensure the third-country manufacturing site has a record retention policy equivalent to EU requirements. Section 5.5 covers split consignments: where batches have been subdivided and the individual quantities imported separately, documentation confirming reconciliation of the quantities should be made available at the site responsible for QP certification, and any discrepancy should be investigated under the responsibility of the certifying QP. In practice that means each partial receipt should carry the parent batch identity, so the reconciliation can be produced from records rather than rebuilt from shipping paperwork.
08Connect batch identity, import events and decision evidence
For medicinal-product importation, an illustrative relationship model connects each batch to responsible sites, import events, versioned evidence and QP decisions. These are proposed implementation fields, not a regulatory data schema:
| Relationship | Illustrative fields |
|---|---|
| Batch → responsible sites | batch_key, site_id, responsibility |
| Batch → import events | batch_key, shipment_id, receipt_id, event_time |
| Batch → versioned evidence | batch_key, document_id, version |
| Batch → QP decisions | batch_key, decision_id, evidence_version_refs, decision_time, approver |
Keep batch identity separate from shipment identity. A batch may arrive through several receipts; a shipment may contain several batches. A receipt answers what arrived, where and when—not which manufacturing batch it belongs to. Scope batch identifiers by product and manufacturer to avoid collisions.
Assign one authoritative record for each datum and define which systems consume it. A practical allocation is:
- ERP or WMS: received quantities and inventory status.
- LIMS: sample identities and analytical results; define identifier mappings for laboratory integration.
- QMS: deviations, investigations and their disposition.
- Controlled document repository: versioned authorisation references and agreements.
Reject or queue unknown batch identifiers; detect duplicate receipt messages before posting quantities. Flag missing document versions and inconsistent units rather than guessing conversions. Track delayed decision messages through acknowledgements, exception queues and reconciliation between sending and receiving records. Never interpret a missing message as permission to progress.
This is a workflow design principle, separate from legislation and GMP guidance: systems can organise evidence and communicate controlled statuses, including an electronic release record. Authorised people assess exceptions and make the applicable certification and release decisions; message delivery is not a substitute for those decisions.
Batch
Product and authorisation identity.
- batch_id
- product_id
- authorisation_ref
Responsible Site
Authorised activity ownership.
- site_id
- mia_ref
- activity_scope
Import Event
Physical movement evidence.
- import_id
- batch_id
- site_id
- customs_clearance_ref
Evidence Package
Versioned records and exceptions.
- evidence_id
- batch_id
- document_version
- deviation_id
QP Decision
Attributable batch decision.
- qp_decision_id
- batch_id
- qp_identity
- decision_timestamp
- decision_status
09Importation failure modes and controlled exception recovery
These are illustrative operational risks for an importation route, not ranked inspection findings or universal mandatory controls. Suggested recovery owners coordinate the work; they do not replace authorised quality decisions.
| Failure mode | Observable evidence gap | Practical control | Recovery owner |
|---|---|---|---|
| Mismatched batch identities | Receipt and certificate identifiers differ | Reconcile identifiers against source records | Warehouse and quality |
| Inaccessible batch documents | Reviewers cannot retrieve referenced records | Test access; obtain controlled copies | Importing MIA quality team |
| Incomplete test panel | Results omit an applicable test | Compare results against applicable testing basis | QC and quality |
| Unsupported agreement reliance | Claimed testing exemption lacks applicability evidence | Document agreement scope and route applicability | Regulatory affairs and QP |
| Unresolved transport damage | Damage report lacks impact assessment | Link shipment evidence to quality assessment | Logistics and quality |
| Inconsistent certification or inventory messages | Stock status conflicts with QP decision | Reconcile decision records and downstream status | Quality and system owners |
For transport exceptions, connect the case record to the product quality review: Annex 21, section 3.2 recommends that PQRs include review of transportation deviations up to batch certification. Assess the actual shipment evidence rather than inventing generic temperature limits, transit durations or acceptance criteria.
Controlled recovery sequence
- Identify the affected batch and shipment.
- Maintain the appropriate restricted status.
- Record the discrepancy and affected decisions.
- Obtain an authorised quality assessment.
- Correct or supplement evidence with version traceability; use an audit trail review workflow where relevant.
- Reconcile affected systems, including inventory status and decision messages.
- Resume only through the appropriate authorised decision.
Disposition and elapsed time depend on the actual quality assessment; not every exception follows the same outcome or timetable.
One-batch traceability challenge
Starting from one received batch, retrieve its physical-import event, responsible MIA sites, applicable testing basis, outstanding exceptions and QP decision evidence, including any electronic release record. Apply the documentation principles covered above. Record broken links as improvement actions; this is a practical traceability exercise, not an official inspection protocol.
10Annex 21 versus Annex 16 and neighbouring GMP guidance
Annex 21 is an importation-specific layer of EU GMP guidance, not a replacement for the wider GMP framework. Annex 21, section 1 directs readers to the main chapters and other annexes, as appropriate to the activities carried out.
| Framework | Main question | Relationship to importation |
|---|---|---|
| Annex 21 | How does GMP apply in the importation setting? | Addresses the MIA holder importing medicinal products from outside the EU/EEA, within the scope defined above. |
| Annex 16 | How are QP certification and batch release addressed? | Its Scope statement identifies QP certification and batch release within the EU as its focus. |
| Annex 13 | Which guidance addresses investigational medicinal products? | Provides the investigational-medicinal-product GMP reference, rather than a general importation framework. |
| Annex 1 | Which guidance addresses sterile manufacture? | Provides the sterile-medicinal-product manufacturing reference, rather than a general importation framework. |
The European Commission’s EudraLex Volume 4 index identifies Annex 13 and Annex 1 by those subjects. Their titles do not, by themselves, establish which detailed provisions apply to a particular product or operation.
For the certification-versus-stock-transfer distinction, use the lifecycle discussed above. International testing arrangements belong in the importation-testing assessment; this comparison does not establish equivalence between jurisdictions’ import rules.
11Implementation and review checklist for an importation route
Annex 21, section 3.1 recommends a Pharmaceutical Quality System aligned with Chapter 1 and detailed appropriately for the importation activities performed. Use the following practical checklist within that PQS; its format and owner assignments are suggestions, not prescribed requirements.
| Check | Suggested owner | Retrievable record |
|---|---|---|
| Route and product classification | Regulatory affairs | Route map and documented scope assessment |
| MIA activity allocation | Importer quality lead | Site/activity matrix linked to authorisations |
| Applicable MA or CTA | Regulatory affairs | Current authorisation references and product particulars |
| Written agreements | Quality lead | Approved agreements and responsibility matrix |
| Testing or agreement reliance | QC lead with QP | Test matrix and documented reliance assessment |
| Receipt and quarantine | Warehouse lead | Receipt record and stock-status history |
| Evidence access | Document control | Record index and access-check results |
| Exception ownership | Quality lead | Assigned deviation, disposition and closure evidence |
| QP decision | Certifying QP | Batch-linked certification or confirmation record |
| Downstream status reconciliation | Inventory lead | Reconciliation of QP decision and destination stock status |
For ongoing product review, Annex 21, section 3.2 says the QP-certification site should perform Product Quality Reviews for imported products, including those imported for further processing before export, except investigational medicinal products.
As a separate risk-based practice, have the route owner reassess this checklist when relevant sites, product authorisations, testing arrangements, agreements or interfaces change. Record the impact assessment, actions and approval in change control. These are suggested review triggers, not a universal mandatory interval or a replacement for ongoing product review.
Frequently asked questions
Q.Can the site of physical importation differ from the site responsible for QP certification?+
Yes. Annex 16, section 1.3 recognises that several sites may participate in importation, testing and storage before certification. The certifying QP remains responsible for ensuring that all necessary steps have been completed. Annex 21, section 5.1 addresses documentation access for the participating MIA holders, aligned with their activities and written agreements. A practical arrangement identifies who receives goods, who supplies records and who resolves discrepancies before batch release.
Q.Does a third-country Certificate of Analysis replace EU/EEA importation testing?+
No. A certificate of analysis supports, but does not by itself replace, the testing basis that applies to the batch. The applicability assessment and the limited exceptions are set out in the importation-testing section above; record which basis was used for each batch. See also Annex 21.
Q.What should an importer establish before relying on an MRA or ACAA for testing relief?+
Confirm that the agreement actually covers the product, the manufacturing site and the activity concerned, and keep that assessment with the batch evidence. The conditions for testing relief are explained in the importation-testing section; this FAQ adds only that the assessment should be repeated when the product, site or agreement scope changes.
Q.Must the QP-certification site review every complete batch record at the same frequency?+
Not necessarily. Annex 21, section 5.1.1 expects the review frequency for full batch documentation to be justified on a risk-assessment basis and defined in the Pharmaceutical Quality System, while the documents supporting certification remain accessible. The documentation section above covers how to separate availability from review depth.
Q.How should a shipment with missing documents or transport damage be handled while the issue is assessed?+
Keep the shipment under controlled quarantine status while its disposition is assessed. Annex 21, section 4.2 describes quarantine after receipt until the appropriate release, certification or confirmation. Practically, record missing documents, photograph damage, preserve transport evidence and route the issue to responsible quality personnel. Annex 16, section 1.5.3 says the QP should consider storage and transport conditions before certification. Receipt into a warehouse should not be treated as resolution of the quality concern.
Q.Can a product intended for export still fall within Annex 21 if it is processed in the EU/EEA?+
Yes. An export destination does not, by itself, remove imported products from Annex 21's import-control framework. Annex 21, section 3.2 expressly includes products imported for further processing before export in its Product Quality Review recommendation, with an exception for investigational medicinal products. For an operational assessment, map the imported material, processing steps and intended destination rather than relying only on the final sales market. The APR/PQR process is one concrete control to examine.
Q.Should investigational medicinal products follow the same import-testing route as products with a marketing authorisation?+
Do not automatically apply the marketing-authorisation testing route to investigational medicinal products. Annex 21, section 2.4 includes IMPs in its manufacturing-standard assurance statement, but expressly attaches its importation-testing statement to products with a marketing authorisation. It points readers to Annex 13 for IMP guidance. Use Annex 13 and the applicable clinical-trial framework to determine the route; this distinction alone is not evidence that an IMP needs no testing.
Q.What evidence distinguishes a QP certification decision from the subsequent transfer to saleable stock?+
Annex 21, section 5.1.1 calls for documentary evidence that the QP certified or confirmed the batch, and Annex 16 places certification before transfer to saleable stock. Keep the QP's batch decision and the later inventory-status transaction as separate, linked records; the importation workflow section above describes the sequence.
Primary sources
Want to see how EU GMP Annex 21 (Importation) could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.
